Fermenta Biotech Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹133 Cr +1.9% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
FB

Fermenta Biotech Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Fermenta Biotech Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹137Cr
−12.2% YoY
+5.5% QoQ
Net profit
₹12Cr
−68.3% YoY
−33.3% QoQ
Margin
18.17%
−15.9 pp YoY
−2.3 pp QoQ

Based on Fermenta Biotech Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹478
Market cap₹1.4K Cr
P/E25.5

The short version

Q3FY26 Revenue: INR 140.5 crore (down 11% YoY, up 4% QoQ) - 9moFY26 Revenue: INR 421.2 crore (up 25% YoY) - Q3FY26 EBITDA: INR 28.1 crore (down 49% YoY, down 12% QoQ) - 9moFY26 EBITDA: INR 97.2 Q3FY26 EBITDA: INR 28.1 crore, down 49% YoY - Q3FY26 Profit after Tax (PAT): INR 12.0 crore, down 68% YoY - Q3FY26 Revenue: INR 140.5 crore, down 11% YoY (for context)

From Fermenta Biotech Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3FY26 Revenue: INR 140.5 crore (down 11% YoY, up 4% QoQ)
  • 9moFY26 Revenue: INR 421.2 crore (up 25% YoY)
  • Q3FY26 EBITDA: INR 28.1 crore (down 49% YoY, down 12% QoQ)
  • 9moFY26 EBITDA: INR 97.2 crore (up 20% YoY)
  • Q3FY26 Profit after tax: INR 12.0 crore (down 68% YoY, down 33% QoQ)
  • 9moFY26 Profit after tax: INR 51.7 crore (up 20% YoY)
  • Human nutrition segment volumes grew 46% over 9MFY25
  • Animal nutrition segment volumes grew 52% over 9MFY25, despite an 8% decline in average realization

2 more points from Fermenta Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

While it highlights: - Strategic manufacturing footprint with multiple locations (Kullu, Dahej, Thane, Pennepalli) - Innovation hub and pilot plant for process development - Collaboration with a German toll manufacturer for Vitamin D3 feed-grade powder production The focus is on current manufacturing capabilities and R&D facilities rather than new or expanded plant projects.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.

Fermenta Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Fermenta Biotech Ltd Q3 FY26 results — key figures

Fermenta Biotech Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue137156-12.2%130+5.5%
Operating profit (EBITDA)2553-53.1%27-6.3%
Operating margin18.17%34.04%-15.9 pp20.46%-2.3 pp
Profit before tax1745-61.4%24-27.4%
Net profit (PAT)1238-68.3%18-33.3%
EPS (₹)4.3112.54-65.6%6.14-29.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Fermenta Biotech Ltd Q3 FY26 results?

Q3FY26 Revenue: INR 140.5 crore (down 11% YoY, up 4% QoQ) - 9moFY26 Revenue: INR 421.2 crore (up 25% YoY) - Q3FY26 EBITDA: INR 28.1 crore (down 49% YoY, down 12% QoQ) - 9moFY26 EBITDA: INR 97.2 Q3FY26 EBITDA: INR 28.1 crore, down 49% YoY - Q3FY26 Profit after Tax (PAT): INR 12.0 crore, down 68% YoY - Q3FY26 Revenue: INR 140.5 crore, down 11% YoY (for context)

What is Fermenta Biotech Ltd share price analysis?

Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.